What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
How can orphan drug manufacturers demonstrate value and improve access to drugs?
Assessing the global challenges inhibiting immuno-oncology market access.
Putting the who, where and why of real-world studies into context.
A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.